Zimmer Biomet Holdings ((ZBH)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Zimmer Biomet Holdings is conducting a Post-market Clinical Follow-up (PMCF) study titled ‘Post-market Clinical Follow-up Study to Provide Safety, Performance and Clinical Benefits Data of the Anatomical Shoulderᵀᴹ 2.0 Fracture System.’ The study aims to gather long-term data on the safety, performance, and clinical benefits of the Anatomical Shoulder 2.0 Fracture System used in shoulder arthroplasty. The primary focus is on safety, specifically implant survivorship, while secondary objectives include performance and clinical benefits through patient-reported outcomes and radiographic data.
The intervention being tested is the Anatomical Shoulder 2.0 Fracture System, designed for fracture shoulder arthroplasty. This system includes implants and instrumentation intended to improve surgical outcomes for patients with shoulder fractures.
This observational study follows a cohort model and includes both retrospective and prospective data collection. It is non-randomized and non-controlled, focusing on real-world application and outcomes. The primary purpose is to assess the safety and effectiveness of the intervention in a clinical setting.
The study began on February 17, 2022, and is currently recruiting participants. The last update was submitted on August 12, 2025. These dates are crucial as they indicate the study’s progress and current status, which can influence investor confidence and market perception.
The ongoing study could impact Zimmer Biomet’s stock performance positively by demonstrating the effectiveness of their products, potentially increasing investor confidence. As the company competes in the orthopedic device market, successful results could enhance its competitive position.
The study is ongoing, with further details available on the ClinicalTrials portal.